Edwin de Graaf is founder and managing partner of Gilde Healthcare. Edwin joined Gilde in 1997 following a career of 3 years as a tax consultant with Coopers & Lybrand (now PwC). He is co-responsible for fund management and investment activities of the healthcare venture and growth capital funds and is head of responsible and impact investment.

Edwin de Graaf is a Dutch national and holds a master’s degree in Business and Fiscal Economics from the Erasmus University Rotterdam. He led investments in AM-Pharma (sale minority interest and option agreement with Pfizer), GlycArt (trade sale to Roche), IDEA (license to Alpharma Pharmaceuticals), Omegatech (trade sale to Martek Biosciences, now DSM), Pieris Pharmaceuticals Inc. (Nasdaq: PIRS), Prosonix (trade sale to Circassia), Sanifit Therapeutics, Santaris Pharma (trade sale to Roche), uniQure (Nasdaq: QURE) and WITHINGS and was involved with investments and divestments including adcendo, Ascendis Pharma (Nasdaq: ASND), Definiens (trade sale to AZ/MedImmune), Moximed, ProQr (Nasdaq: PRQR), ProFibrix (trade sale to The Medicines Company) and Sapiens (trade sale to Medtronic). He represented Gilde on the boards of AM Pharma, Ascendis Pharma, Glycart, IDEA, Pieris, Prosonix, Sanifit Therapeutics, Santaris Pharma and uniQure and currently serves on the board WITHINGS and adcendo.